Clinical-record digest / About
About Rx Tesamorelin
An independent editorial reading of the tesamorelin literature — what the trials established, and where the approved indication ends.
What this site is
Rx Tesamorelin is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature on tesamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site reads tesamorelin's literature the way a clinical record reads — figure by figure, traced to source. That literature is unusually clean for its compound class: a narrow FDA approval (NDA 022505, 2010, for HIV-associated lipodystrophy), two pivotal Phase 3 trials, a JAMA hepatic-steatosis trial, a Lancet HIV fatty-liver trial, and a 2026 meta-analysis. We summarize what those studies measured and mark the line where the approved indication ends and the off-label questions begin.
What the 'Rx' in the name means
The 'Rx' in Rx Tesamorelin is editorial framing, not a service. It signals the register this publisher occupies relative to the literature — a measured, regulatory-precise reading of the evidence, the way a prescribing-information document is precise about indication and scope. It does not mean this site prescribes, dispenses, or fills anything, and it does not imply a pharmacy, a consultation, or any healthcare service.
We hold a single distinction at the center of everything here: tesamorelin is a real, FDA-approved prescription drug, but only for HIV-associated lipodystrophy. Every other use is off-label and investigational. We state that scope precisely rather than blurring it, because the blurring is exactly what an honest reading of this evidence has to resist.
How we handle sources
Every quantitative claim on this site — every percentage, dose, n-value, and half-life — is tied to a numbered citation on the references page, drawn from PubMed-indexed journals, the NIH LiverTox monograph, and published meta-analyses. We describe research findings in studied populations. We do not extrapolate to populations the trials did not test, and we give no human dosing instructions, because research-grade tesamorelin is not an approved finished medicine to self-administer. Where the data stop, we say so.